Lihua Wang

ORCID: 0000-0001-5783-6317
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Asthma and respiratory diseases
  • Neuroendocrine Tumor Research Advances
  • Coronary Interventions and Diagnostics
  • Cardiac Imaging and Diagnostics
  • Dysphagia Assessment and Management
  • Restless Legs Syndrome Research
  • Allergic Rhinitis and Sensitization
  • Advanced X-ray and CT Imaging
  • Pancreatitis Pathology and Treatment
  • Child Nutrition and Feeding Issues
  • Dermatology and Skin Diseases
  • IgG4-Related and Inflammatory Diseases

Shandong First Medical University
2024-2025

Second Hospital of Shanxi Medical University
2025

Shanxi Medical University
2025

Jinan Central Hospital
2024-2025

Affiliated Hospital of Nantong University
2023

Nantong University
2023

China-Japan Friendship Hospital
2017

Harrison International Peace Hospital
2017

The deep learning-based high-performance computational fluid dynamics (CFD) solution method is currently a hot, frontier topic in hemodynamic research. However, accurate predictions of the flow field with different coronary geometries and boundary conditions remain challenging. Given this, this study proposes based on learning computed tomography angiography (CTA) that achieves rapid solutions for blood pressure. We established dataset patient-specific data from 370 patients proposed model...

10.1063/5.0246660 article EN Physics of Fluids 2025-02-01

Importance Lupus nephritis is typically treated with intravenous cyclophosphamide, which associated serious adverse effects. Oral mizoribine may be an alternative for induction therapy of lupus nephritis. However, large-scale, long-term, randomized clinical studies are lacking. Objective To assess the efficacy and safety oral vs cyclophosphamide as Chinese patients Design, Setting, Participants This prospective, multicenter, parallel-group, open-label, phase 3 trial recruited class III,...

10.1001/jamanetworkopen.2025.0648 article EN cc-by-nc-nd JAMA Network Open 2025-03-14

Abstract Background Management of moderate‐to‐severe atopic dermatitis (AD) needs long‐term therapy. Stapokibart is a humanized monoclonal antibody targeting interleukin‐4 receptor α subunit (IL‐4Rα), shared for IL‐4 and IL‐13 which are key pathogenic drivers AD. In pivotal phase 3 trial (NCT05265923), significant higher proportions adult AD patients receiving stapokibart than placebo achieved ≥75% improvement from baseline in Eczema Area Severity Index (EASI‐75; 66.9% vs. 25.8%)...

10.1111/all.16368 article EN Allergy 2024-10-25

To investigate the awareness of dysphagia-related complications and risks importance early intervention in patients with Parkinson's disease (PD).Using phenomenological approach qualitative study, 18 PD a Grade A tertiary hospital Nantong were selected, semistructured personal in-depth interviews conducted. The interview content was analyzed using Colaizzi's seven-step method, topics subtopics further refined.Awareness can be summarized into three topics: lack knowledge about dysphagia,...

10.1155/2023/9514851 article EN cc-by International Journal of Clinical Practice 2023-03-03
Coming Soon ...